By Dr. Patricia Gutiérrez Ontalvilla, MD, PhD · Plastic Surgeon and Regenerative Medicine · Specialist in Vulvar Lichen Sclerosus
There’s a phrase I hear often in consultations: “I’ve been promised this can be cured.” And I understand where it comes from. When a patient searches whether tissue can be regenerated in lichen sclerosus, they encounter many promises and little proof. That’s why I prefer to do the opposite: show you what has been published, with its successes and its limitations.
This article isn’t here to sell you anything. It’s here to calmly explain what scientific evidence truly says about the possibility of tissue regeneration, where that evidence originates, and, most importantly, what we still cannot affirm.
Regarding tissue regeneration in lichen sclerosus, published scientific evidence (peer-reviewed clinical research) shows that affected tissue can respond to regenerative therapies using the patient’s own cells. It does not demonstrate a cure: lichen sclerosus is a chronic condition whose course can be modified, not eliminated.
What it Means for Liquenia® to Have Scientific Evidence
When we talk about evidence, we’re not talking about opinions or isolated testimonials. We’re talking about studies designed to reduce bias and published in journals that review the work before accepting it.
The most demanding level of this pyramid is the randomized trial. In it, patients are randomly assigned to receive or not receive an intervention, which allows for more rigorous comparison. The fact that a regenerative approach for lichen sclerosus stems from a randomized trial (level 1) is not a minor detail: it is what separates a hypothesis from a well-founded observation.
Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin disease of the vulva. According to the ISSVD 2016 classification, it is understood as a chronic condition requiring ongoing monitoring. This chronicity is why no serious treatment promises to make it disappear forever.
A fact to put things in perspective: the regenerative evidence published by our team in the Aesthetic Surgery Journal (2025) comes from a study with a sample of 18 patients within a registered trial. It is a small and honest sample: enough to pave the way, insufficient to close the debate.
Where the Evidence Comes From: From Randomized Trial to Stromal Vascular Fraction
The idea of regenerating vulvar tissue didn’t appear suddenly. It’s the result of years of work that have refined the technique.
The starting point was that level 1 randomized trial, which provided the first solid signal that affected tissue could respond to a regenerative approach. From there, the technique evolved towards the use of stromal vascular fraction (SVF) and autologous nanofat: regenerative cells obtained from the patient’s own fat, without donor material.
It is important to be precise with language. We speak of regenerative cells, not “stem cells” in the colloquial and exaggerated sense so often used in advertising. And platelet-rich plasma (PRP), which you will see mentioned in many places, is not part of the current SVF-based protocol: it is a distinct concept, with its own role and limitations.
A reference is not only someone who tells you what they know. It is also someone who sets the limits of what they know.
Dr. Patricia Gutiérrez Ontalvilla
What the Evidence DOES Show About Tissue Regeneration
Despite the noise, there are things that published research does allow us to affirm. And I want to state them with the same clarity with which I will later mark the limits, because being cautious does not diminish the value of what has been proven.
What supports this line of work is not a testimonial or a clinical impression, but peer-reviewed research. The journey began at the most demanding level, the randomized trial, and evolved towards the use of the patient’s own regenerative cells. That is, today, the scientific basis for discussing tissue regeneration when established damage already exists.
- Yes: there is peer-reviewed evidence, not just testimonials (Aesthetic Surgery Journal, 2025).
- Yes: the starting point is a level 1 randomized trial, the most demanding level of evidence.
- Yes: the technique uses the patient’s own regenerative cells (SVF and autologous nanofat), without donor material.
- Yes: affected tissue can respond to the regenerative approach when established damage is present.
However, what does “respond” mean in concrete figures (symptom improvement, observed changes in biopsy)? Specifically, the study published in ASJ (2025, N=18) observed a 76.5% reduction in clinical symptom scores (from a mean of 20.12 to 4.71; $P = .0025$) and a 65.5% decrease in the chronic itching scale, accompanied histologically by a significant reduction in stromal hyalinization ($P = .0036$), a decrease in CD3+ T-cell inflammatory infiltrate ($P = .0068$), and an increase in microvascular density ($P = .0121$) at 12 months.
What the Evidence DOES NOT Say About Tissue Regeneration
This, for me, is the other essential half. Because almost all the noise comes from confusing what a study suggests with what a study proves.
The available evidence does not say that lichen sclerosus is cured. Modifying the course of a disease and curing it are different things. The evidence also does not say that you can stop using corticosteroids: topical corticosteroids, prescribed by your doctor, are still necessary and are the recognized pillar of treatment. Regenerative therapy comes into play when the tissue has already changed, not as a substitute.
And there is an honest methodological limit: samples are still small, and follow-up is limited. This means that anyone who guarantees a “definitive” or “risk-free” result is going beyond what published science currently allows us to affirm.
- No, it does not replace prescribed corticosteroids.
- No, it does not equate to a cure or a guaranteed outcome.
- No, it does not eliminate the need for clinical follow-up and long-term risk control.
Why This Matters to You if You Live with Lichen Sclerosus
Knowing how to distinguish what is proven from what is promised protects you. It helps you ask better questions in consultations and avoid messages that play with your hope.
If you have persistent symptoms (itching, fissures, white plaques, pain during intercourse, or anatomical changes), the first step is not to seek a miraculous treatment, but a medical evaluation with gynecology, dermatology, or a vulvar pathology specialist. The diagnosis, often confirmed by biopsy, determines everything that follows. This is not individual advice: it is guidance to help you take the correct step.
References
- Gutiérrez-Ontalvilla P, et al. Study on regenerative therapy in vulvar lichen sclerosus. Aesthetic Surgery Journal (ASJ), 2025. N=18. Registered trial NCT03961126. DOI: 10.1093/asj/sjaf148.
- International Society for the Study of Vulvovaginal Disease (ISSVD), 2016 classification of vulvar lichen sclerosus (PDF in English).
Frequently asked questions
Can tissue be regenerated in lichen sclerosus?
Published evidence indicates that affected vulvar tissue can respond to regenerative therapies using the patient’s own cells, such as stromal vascular fraction and autologous nanofat, with documented changes in peer-reviewed research. It does not equate to a cure or a guaranteed outcome: samples are small, and follow-up is limited. We are talking about modifying the course of the damage, not eliminating it.
Does scientific evidence say that lichen sclerosus is cured?
No. Published evidence indicates that the course of the disease can be modified and that tissue can respond to regenerative therapies, but it does not demonstrate a cure. Lichen sclerosus is a chronic condition that requires continuous medical monitoring and long-term control.
What is stromal vascular fraction (SVF) in lichen sclerosus?
Stromal vascular fraction is a collection of regenerative cells obtained from the patient’s own fat. It is used to promote the regeneration of affected vulvar tissue. The evidence supporting it comes from a randomized trial and subsequent peer-reviewed research, with still limited samples.
Does regenerative therapy replace corticosteroids?
No. Topical corticosteroids, prescribed by your doctor, remain the recognized pillar of lichen sclerosus treatment. The regenerative approach is considered when the tissue has already changed and never as a substitute for medical treatment. Any changes must be decided by your specialist.
Why distrust those who promise guaranteed results?
Because the evidence published today is based on small samples and limited follow-up. This allows us to speak of tissue regeneration on a scientific basis, but not of guarantees or definitive results. A rigorous professional explains both what they know and the limits of what they know.
Rigorous Information, Without Promises
If you live with vulvar lichen sclerosus and want to understand what scientifically-based regenerative medicine can offer you, you will find updated and honest information in our project.
Further reading: you can expand your knowledge with our article on PRP versus SVF in lichen sclerosus, the review of treatments: PRP, laser, and regenerative cells, and the before and after biopsy results. To learn about Dr. Gutiérrez Ontalvilla’s career and publications, visit dragutierrez.com, and for outreach and research, the Nixarian Foundation.
This content is for informational and educational purposes. It does not substitute for diagnosis or individualized medical advice. For persistent symptoms, consult your gynecology, dermatology, or vulvar pathology team.
